Comparing a new dupilumab medicine to Dupixent in healthy adults
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult between 18 and 55 years old.
- Your weight is between 110 and 210 lbs, and your body mass index is between 18.5 and 29.9.
- You have not taken dupilumab (Dupixent) before.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use birth control if needed.
- You have not participated in another drug trial or taken an experimental medicine in the past 30 days.
- You can avoid smoking more than 5 cigarettes a day and limit caffeine drinks during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
This trial tests whether an experimental medication, QL2108, works as well as a standard treatment (Dupixent) for moderate-to-severe atopic dermatitis (eczema). It may help reduce the severity of eczema symptoms and improve quality of life.
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.